Fri, Jul 11, 2014, 2:47 PM EDT - U.S. Markets close in 1 hr 13 mins

Recent

% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, Inc. Message Board

  • vd6rt vd6rt Dec 30, 2011 5:00 PM Flag

    Check out CYCC - would also benefit from Dacogen approval

    Check out CYCC. Trades near cash value and is in phase 3 trial for AML comparing combo of its Sapacitabine + Decitabine vs. Decitabine alone. Has SPA with FDA. In the near term Seliciclib for NSCLC analysis on whether it is effective on k-RAS mutation was promised by year end 2011. And today stock moved up on high volume and no news.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • MARXE AUSTIN W & GREENHOUSE DAVID been dumping shares in the last few months @ 0.60 like there is no tomorrow!

      I would watch out from CYCC.

      Personal opinion of course.

      Why invest in CYCC if you got ASTX with great cash position of 130M$ plus 60M$ annual income...???

      Right now ASTX seems like the best investment out there.

      I.

      • 1 Reply to ikabro
      • Marxe Austin and Greenhouse don't have any insider info. They dumped for tax loss.
        Also, they are not known for smart trading in CYCC, for example they sold a large chunk 2 years ago in January just 2-3 days before stock soared.

        Anyway, CEO of CYCC just bought at open market. Last time he bought 3 months ago at about the same level and his timing was good.

        Much lower market cap for CYCC means more upside in percentage terms than for ASTX.
        If both drugs - decitabine and sapacitabine would end up been used together in combination therapy, then both companies would have market caps in the same neighborhood, not 3:1 like now.

        CYCC has more risk of course because it is earlier stage and cash bleeding

 
ASTX
8.4950.000(0.00%)Oct 10 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.